MaxCyte, Inc. Files 8-K on Financials

Ticker: MXCT · Form: 8-K · Filed: Nov 6, 2024 · CIK: 1287098

Maxcyte, INC. 8-K Filing Summary
FieldDetail
CompanyMaxcyte, INC. (MXCT)
Form Type8-K
Filed DateNov 6, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, 8-k

Related Tickers: MXCT

TL;DR

MaxCyte dropped an 8-K on Nov 6th covering financials and operations. Check it for the latest.

AI Summary

MaxCyte, Inc. filed an 8-K on November 6, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and headquartered in Rockville, Maryland.

Why It Matters

This 8-K filing provides investors with crucial updates on MaxCyte's financial performance and operational status, impacting investment decisions.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.

Key Players & Entities

FAQ

What specific financial results are being reported in this 8-K?

The filing indicates it pertains to 'Results of Operations and Financial Condition' but does not provide specific figures within the provided text.

Are there any new material agreements or events disclosed?

The filing lists 'Regulation FD Disclosure' and 'Financial Statements and Exhibits' as items, suggesting potential disclosures, but the specifics are not detailed in the provided text.

What is the primary purpose of this 8-K filing?

The primary purpose is to report on the company's results of operations and financial condition, along with any applicable Regulation FD disclosures and financial statements/exhibits.

When was this 8-K filing submitted?

The filing was submitted on November 6, 2024.

Where is MaxCyte, Inc. headquartered?

MaxCyte, Inc. is headquartered at 9713 Key West Avenue, Suite 400, Rockville, Maryland 20850.

Filing Stats: 714 words · 3 min read · ~2 pages · Grade level 11.7 · Accepted 2024-11-06 16:22:47

Key Financial Figures

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On November 6, 2024, MaxCyte, Inc. (the " Company ") issued a press release announcing its financial results for the quarter and nine months ended September 30, 2024. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 hereto, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act ") or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings, except as expressly set forth by specific reference in such a filing.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On November 6, 2024, the Company posted an updated corporate presentation, which the Company may use from time to time in communications or conferences, to its website at https://investors.maxcyte.com. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.2 hereto, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings, except as expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release, dated November 6, 2024 99.2 Corporate Presentation, dated November 2024 104 Cover Page Interactive Data (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MaxCyte, Inc. Dated: November 6, 2024 By: /s/ Douglas Swirsky Douglas Swirsky Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing